| - Industry | - Sector | Mr. Ian Campbell M.Sc. CEO | CNSX Exchange | - ISIN |
| Canada Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Neural Therapeutics Inc. is an ethnobotanical drug discovery company dedicated to developing therapeutic drugs aimed at treating mental illnesses, with a specific focus on substance use disorders, such as alcohol and opioid dependence. The company leverages active substances derived from plants, particularly psychoactive species like the San Pedro cactus, known for its mescaline content. Neural Therapeutics employs an innovative methodology, including the strategic use of sub-hallucinogenic doses of mescaline extracts, aspiring to create safe and scalable therapies for various mental health conditions, such as depression and anxiety, alongside addiction recovery. Additionally, the company seeks to incorporate nutraceutical applications from the non-psychoactive compounds within these plants. Situated in Toronto, Neural Therapeutics harmonizes traditional indigenous wisdom with contemporary scientific advancements to push forward the emergence of novel treatment options for mental health and wellness products. Its commercial activity is expanding through a strategic partnership and significant equity participation in CWE European Holdings Inc., a leading German retail platform focused on hemp and CBD products, operating under the Hanf.com brand. This partnership enhances Neural Therapeutics' presence within the burgeoning European market for natural products.
Neural Therapeutics specializes in the extraction and application of psychoactive compounds, particularly mescaline from the San Pedro cactus. The company focuses on formulating therapies that utilize sub-hallucinogenic doses, aimed at treating conditions such as depression, anxiety, and substance use disorders while minimizing negative side effects.
In addition to pharmaceutical developments, Neural Therapeutics explores nutraceutical applications derived from non-psychoactive compounds found within ethnobotanical sources. This includes the design of wellness products that harness the health benefits of these plants, supporting overall mental well-being.
The company is engaged in rigorous research and development efforts to discover novel therapeutic drugs aimed at addressing mental health conditions. This includes comprehensive studies that integrate traditional indigenous knowledge with modern research methodologies to ensure efficacy and safety.
Neural Therapeutics seeks to augment its capabilities and market reach through strategic partnerships, such as its notable equity stake in CWE European Holdings Inc. This collaboration affords the company a stronger foothold in the European natural products market and paves the way for shared expertise in product development and distribution.